Detalhe da pesquisa
1.
Metabolism and Disposition of Ataluren after Oral Administration to Mice, Rats, Dogs, and Humans.
Drug Metab Dispos
; 48(4): 317-325, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31980502
2.
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 390(10101): 1489-1498, 2017 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28728956
3.
Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma.
Haematologica
; 108(5): 1412-1416, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36475521
4.
Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial.
Muscle Nerve
; 58(5): 639-645, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30028519
5.
The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma.
Biomark Res
; 12(1): 62, 2024 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38886769
6.
The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma.
Exp Hematol Oncol
; 13(1): 14, 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38326887
7.
Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins.
Cell Death Dis
; 14(11): 714, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37919300
8.
Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
J Clin Invest
; 133(3)2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36719376
9.
Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.
J Hematol Oncol
; 15(1): 42, 2022 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35410313
10.
Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials.
J Cyst Fibros
; 20(1): 39-45, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32682670
11.
The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
J Hematol Oncol
; 14(1): 132, 2021 08 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34454548
12.
Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.
Nat Commun
; 12(1): 2877, 2021 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34001881
13.
Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy.
J Comp Eff Res
; 9(14): 973-984, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32851872
14.
Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects.
Clin Pharmacol Drug Dev
; 8(2): 172-178, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30629861
15.
The relationship between deficit in digit span and genotype in nonsense mutation Duchenne muscular dystrophy.
Neurology
; 91(13): e1215-e1219, 2018 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30135256
16.
Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma.
Blood Adv
; 7(14): 3361-3365, 2023 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37257192
17.
Assessment of Treatment Effect With Multiple Outcomes in 2 Clinical Trials of Patients With Duchenne Muscular Dystrophy.
JAMA Netw Open
; 3(2): e1921306, 2020 02 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32058550
18.
Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses.
J Immunol
; 173(12): 7324-30, 2004 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15585856